Research Article| Volume 217, P1-6, August 15, 2016

Download started.


Aortic valve sclerosis as a marker of atherosclerosis: Novel insights from hepatic steatosis



      Nowadays, aortic valve sclerosis (AVSc) might be considered an atherosclerosis-like process due to significant association with age, male gender and some major features of metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD) has been recognized as a clinical expression of the metabolic syndrome and as a predictor of cardiovascular events. We aim, with this meta-analysis, to evaluate the correlation between NAFLD and AVSc; this finding might suggest new insights and interactions among NAFLD, AVSc and the atherosclerotic process.

      Methods and results

      A detailed search was conducted according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines to identify all studies providing data about the association between AVSc and NAFLD. 3 studies enrolling a total of 1172 patients with NAFLD and 1467 controls without NAFLD were included in the meta-analysis. The prevalence of AVSc was 41.3% (95% CI: 32.0%, 51.4%) in NAFLD patients and 24.6% (18.4%, 32.0%) in subjects without NAFLD with a corresponding OR of 2.28 (95% CI: 1.21, 4.28, p = 0.01, I2: 77.6%, p = 0.011). A meta-regression analysis showed that age, prevalence of male gender, hypertension, body mass index, and dyslipidemia were directly and significantly associated with the difference in the prevalence of AVSc between patients with NAFLD and those without.


      In conclusion, our meta-analysis shows a significant association between NAFLD and AVSc. However, further evidence is needed to validate these findings and find out if there is a real link or just a mere association.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gharacholou S.M.
        • Karon B.L.
        • Shub C.
        • Pellikka P.A.
        Aortic valve sclerosis and clinical outcomes: moving toward a definition.
        Am. J. Med. 2011; 124: 103-110
        • Otto C.M.
        • Kuusisto J.
        • Reichenbach D.D.
        • Gown A.M.
        • O'Brien K.D.
        Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies.
        Circulation. 1994; 90: 844-853
        • Coffey S.
        • Cox B.
        • Williams M.J.
        The prevalence, incidence, progression, and risks of aortic valve sclerosis: a systematic review and meta-analysis.
        J. Am. Coll. Cardiol. 2014; 63: 2852-2861
        • Korkmaz L.
        • Agac M.T.
        • Bektas H.
        • Varol M.O.
        • Erkan H.
        • Acar Z.
        • et al.
        Aortic valve sclerosis is a sign of increased arterial stiffness in clinically asymptomatic subjects.
        Cardiol. J. 2013; 20: 318-322
        • Tarantino G.
        • Saldalamacchia G.
        • Conca P.
        • Arena A.
        Non-alcoholic fatty liver disease: further expression of the metabolic syndrome.
        J. Gastroenterol. Hepatol. 2007; 22: 293-303
        • Mantovani A.
        • Ballestri S.
        • Lonardo A.
        • Targher G.
        Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease.
        Dig. Dis. Sci. 2016;
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • Group P.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        PLoS Med. 2009; 6e1000097
        • Juni P.
        • Witschi A.
        • Bloch R.
        • Egger M.
        The hazards of scoring the quality of clinical trials for meta-analysis.
        J. Am. Med. Assoc. 1999; 282: 1054-1060
        • Higgins J.P.
        • Thompson S.G.
        • Deeks J.J.
        • Altman D.G.
        Measuring inconsistency in meta-analyses.
        BMJ. 2003; 327: 557-560
        • Sterne J.A.
        • Egger M.
        • Smith G.D.
        Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis.
        BMJ. 2001; 323: 101-105
        • Bonapace S.
        • Valbusa F.
        • Bertolini L.
        • Pichiri I.
        • Mantovani A.
        • Rossi A.
        • et al.
        Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus.
        PLoS ONE. 2014; 9e88371
        • Mantovani A.
        • Pernigo M.
        • Bergamini C.
        • Bonapace S.
        • Lipari P.
        • Valbusa F.
        • et al.
        Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease.
        Metabolism. 2015; 64: 879-887
        • Markus M.R.
        • Baumeister S.E.
        • Stritzke J.
        • Dorr M.
        • Wallaschofski H.
        • Volzke H.
        • et al.
        Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP).
        Arterioscler. Thromb. Vasc. Biol. 2013; 33: 1690-1695
        • Sainger R.
        • Grau J.B.
        • Branchetti E.
        • Poggio P.
        • Lai E.
        • Koka E.
        • et al.
        Comparison of transesophageal echocardiographic analysis and circulating biomarker expression profile in calcific aortic valve disease.
        J. Heart Valve Dis. 2013; 22: 156-165
        • Luo J.
        • Xu L.
        • Li J.
        • Zhao S.
        Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
        Eur. J. Gastroenterol. Hepatol. 2015; 27: 193-199
        • Di Minno M.N.
        • Russolillo A.
        • Lupoli R.
        • Ambrosino P.
        • Di Minno A.
        • Tarantino G.
        Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.
        World J. Gastroenterol. 2012; 18: 5839-5847
        • Scalera A.
        • Di Minno M.N.
        • Tarantino G.
        What does irritable bowel syndrome share with non-alcoholic fatty liver disease?.
        World J. Gastroenterol. 2013; 19: 5402-5420
        • Day C.P.
        • James OF
        Steatohepatitis: a tale of two “hits”?.
        Gastroenterology. 1998; 114: 842-845
        • Portincasa P.
        • Grattagliano I.
        • Palmieri V.O.
        • Palasciano G.
        Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management.
        Clin. Biochem. 2005; 38: 203-217
        • Mohler 3rd, E.R.
        • Gannon F.
        • Reynolds C.
        • Zimmerman R.
        • Keane M.G.
        • Kaplan F.S.
        Bone formation and inflammation in cardiac valves.
        Circulation. 2001; 103: 1522-1528
        • Poggio P.
        • Branchetti E.
        • Grau J.B.
        • Lai E.K.
        • Gorman R.C.
        • Gorman 3rd, J.H.
        • et al.
        Osteopontin–CD44v6 interaction mediates calcium deposition via phospho-Akt in valve interstitial cells from patients with noncalcified aortic valve sclerosis.
        Arterioscler. Thromb. Vasc. Biol. 2014; 34: 2086-2094
        • Branchetti E.
        • Sainger R.
        • Poggio P.
        • Grau J.B.
        • Patterson-Fortin J.
        • Bavaria J.E.
        • et al.
        Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis.
        Arterioscler. Thromb. Vasc. Biol. 2013; 33: e66-e74
        • Vilar C.P.
        • Cotrim H.P.
        • Florentino G.S.
        • Barreto C.P.
        • Florentino A.V.
        • Bragagnoli G.
        • et al.
        Association between nonalcoholic fatty liver disease and coronary artery disease.
        Rev. Assoc. Med. Bras. 2013; 59: 290-297
        • Gaggini M.
        • Morelli M.
        • Buzzigoli E.
        • DeFronzo R.A.
        • Bugianesi E.
        • Gastaldelli A.
        Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease.
        Nutrients. 2013; 5: 1544-1560
        • Arslan U.
        • Turkoglu S.
        • Balcioglu S.
        • Tavil Y.
        • Karakan T.
        • Cengel A.
        Association between nonalcoholic fatty liver disease and coronary artery disease.
        Coron. Artery Dis. 2007; 18: 433-436
        • Mazzone A.
        • Venneri L.
        • Berti S.
        Aortic valve stenosis and coronary artery disease: pathophysiological and clinical links.
        J. Cardiovasc. Med. (Hagerstown). 2007; 8: 983-989
        • Otto C.M.
        Why is aortic sclerosis associated with adverse clinical outcomes?.
        J. Am. Coll. Cardiol. 2004; 43: 176-178
        • Pomerance A.
        Pathogenesis of aortic stenosis and its relation to age.
        Br. Heart J. 1972; 34: 569-574
        • Roberts W.C.
        The senile cardiac calcification syndrome.
        Am. J. Cardiol. 1986; 58: 572-574
        • Sathyamurthy I.
        • Alex S.
        Calcific aortic valve disease: is it another face of atherosclerosis?.
        Indian Heart J. 2015; 67: 503-506
        • Abdelbaky A.
        • Corsini E.
        • Figueroa A.L.
        • Subramanian S.
        • Fontanez S.
        • Emami H.
        • et al.
        Early aortic valve inflammation precedes calcification: a longitudinal FDG-PET/CT study.
        Atherosclerosis. 2015; 238: 165-172